• <a fr-original-style="" href="https://www.reuters.com/markets/deals/pfizer-joins-beam-therapeutics-develop-rare-disease-therapies-2022-01-10/" rel="noopener noreferrer" style="color: rgb(9, 9, 9); text-decoration: none; background-color: transparent; outline: none; cursor: pointer; transition: color 0.3s ease 0s; touch-action: manipulation; user-select: auto; box-sizing: border-box;" target="_blank">Pfizer</a> furthered the use of their mRNA technology behind their Covid-19 vaccine, signing three deals including a contract worth $1.35 billion (€1.2bn) with Beam Therapeutics for treatments of genetic diseases.<ul fr-original-style="padding-inline-start: 20px;" style="padding-inline-start: 20px; margin-top: 0px; margin-bottom: 1em; list-style-position: inside; box-sizing: border-box;"><li fr-original-style="" style="box-sizing: border-box;">Furthermore: Pfizer CEO Albert Bourla said that he remained unsure of the necessity of the fourth dose of their COVID-19 shot to booster immunity against the Omicron variant of the coronavirus.</li></ul>

booster immunity ile ilgili hikayeler